Safety and clinical activity of 1L atezolizumab+ bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).

S Stein, MJ Pishvaian, MS Lee, KH Lee, S Hernandez… - 2018 - ascopubs.org
4074 Background: Advanced HCC is a lethal cancer with a high unmet medical need. Single-
agent immunotherapy with PD-L1/PD-1 blockade or treatment (Tx) with anti-angiogenic …
被引用次数：133 相关文章

[引用][C] Safety and clinical activity of 1L atezolizumab+ bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).

S Stein, MJ Pishvaian, MS Lee, KH Lee… - Journal of Clinical …, 2018 - cir.nii.ac.jp
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in
hepatocellular carcinoma (HCC). | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …